Recombinant Human Arginase I (rhArgI) for Patients With Advanced Hepatocellular Carcinoma (HCC): An Adaptive Design Dose Escalation Trial With Addition of Standard Doxorubicin Treatment.
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2012
At a glance
- Drugs BCT 100 (Primary) ; Doxorubicin
- Indications Liver cancer
- Focus Pharmacokinetics; Therapeutic Use
- 13 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Oct 2009 New trial record